Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.41 USD | +2.31% | +7.27% | +43.03% |
May. 23 | Cogent Reports Positive Cancer Combo Treatment Trial Data; Names Commercial Chief | MT |
May. 23 | Cogent Biosciences, Inc. Announces the Appointment of Cole Pinnow as Chief Commercial Officer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+43.03% | 786M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- COGT Stock
- News Cogent Biosciences, Inc.
- Wedbush Adjusts Cogent Biosciences' Price Target to $21 From $19; Outperform Rating Kept